You are about to leave the Clinical Value website now.

Cancel

Get the latest updates in the liver space with our HCC detection (HD) expert pack

Get the latest updates in the liver space with our HCC detection (HD) expert pack

Includes

  • Highlights and a PDF copy of the latest APAC regional consensus for PIVKA-II and AFP in HCC
  • APASL 2023 Congress Report
  • Updates on future studies and patient cases

About 1 in 3 early hepatocellular carcinoma (HCC) patients
are missed with current standard of care 1

 
patients image
 

Ultrasound + AFP has only 63% sensitivity in detecting early stage HCC2

37% are missed

This means that 37% patients are missing out on potentially curative HCC treatment.

Download the free HD expert pack

The gaps in current standard of care

Ultrasound3

  • Operator variability
  • Poor performance in patients with fibrotic changes and fatty infiltration of the liver
  • Difficult to perform on obese patients 
  • Difficult to detect small tumors (< 2cm)
  • Limited capacity in public hospitals and rural settings

AFP3-5

Sensitivity and specificity depends on cut-off values used AFP can be elevated (false positive) in:
  • Cirrhosis
  • Active hepatitis
  • Other types of tumors
AFP can be normal (false negative) in:
  • Certain HCC patients have normal AFP throughout the entire disease course. This can be dependent on the etiology of the disease (e.g. high prevalence of AFP-negative in patients with fatty liver disease  induced HCC)
  • Small HCC tumors (<2cm)

PIVKA-II + AFP improves detection of early HCC with increased sensitivity compared to AFP alone

PIVKA-II is a protein that is elevated in the liver under certain circumstances, such as HCC and Vitamin K deficiency6,7.

In the recent 2022 'Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region', experts agree that PIVKA-II, when combined with AFP, improves the detection of HCC, compared to either biomarker alone4.

Experts also agree that PIVKA-II is valuable in the detection of HCC in AFP-negative HCC patients4.

Many patients with HCC are AFP-negative (defined as AFP ≤20 ng/ml)

Almost Half (46%) of 1,158 patients with HCC were AFP-negative10

PIVKA-II can detect up to 76% of patients with AFP-negative HCC11

Sensitivity

Specificity

AUC

References:

  1. Hanouneh, I. A., Alkhouri, N., & Singal, A. G. (2019). Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?. Clinical and molecular hepatology, 25(3), 264–269. https://doi.org/10.3350/cmh.2019.1001
  2. Tzartzeva, K., Obi, J., Rich, N. E., Parikh, N. D., Marrero, J. A., Yopp, A., Waljee, A. K., & Singal, A. G. (2018). Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology, 154(6), 1706–1718.e1. https://doi.org/10.1053/j.gastro.2018.01.064
  3. Simmons, O., Fetzer, D. T., Yokoo, T., Marrero, J. A., Yopp, A., Kono, Y., Parikh, N. D., Browning, T., & Singal, A. G. (2017). Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Alimentary pharmacology & therapeutics, 45(1), 169–177. https://doi.org/10.1111/apt.13841
  4. Kim, D. Y., Toan, B. N., Tan, C. K., Hasan, I., Setiawan, L., Yu, M. L., Izumi, N., Huyen, N. N., Chow, P. K., Mohamed, R., Chan, S. L., Tanwandee, T., Lee, T. Y., Hai, T. T. N., Yang, T., Lee, W. C., & Chan, H. L. Y. (2023). Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clinical and molecular hepatology, 29(2), 277–292. https://doi.org/10.3350/cmh.2022.0212
  5. Tokushige, K., Hyogo, H., Nakajima, T., Ono, M., Kawaguchi, T., Honda, K., Eguchi, Y., Nozaki, Y., Kawanaka, M., Tanaka, S., Imajo, K., Sumida, Y., Kamada, Y., Fujii, H., Suzuki, Y., Kogiso, T., Karino, Y., Munekage, K., Kuromatsu, R., Oeda, S., … Hashimoto, E. (2016). Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. Journal of gastroenterology, 51(6), 586–596. https://doi.org/10.1007/s00535-015-1129-1
  6. Liebman, H. A., Furie, B. C., Tong, M. J., Blanchard, R. A., Lo, K. J., Lee, S. D., Coleman, M. S., & Furie, B. (1984). Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. The New England journal of medicine, 310(22), 1427–1431. https://doi.org/10.1056/NEJM198405313102204
  7. Ono, M., Ohta, H., Ohhira, M., Sekiya, C., & Namiki, M. (1990). Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 11(6), 319–326. https://doi.org/10.1159/000217667 
  8. Chen, H., Chen, S., Li, S., Chen, Z., Zhu, X., Dai, M., Kong, L., Lv, X., Huang, Z., & Qin, X. (2017). Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study. Oncotarget, 8(52), 90390–90401. https://doi.org/10.18632/oncotarget.20153 
  9. Xu, F., Zhang, L., He, W., Song, D., Ji, X., & Shao, J. (2021). The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Disease markers, 2021, 8868370. https://doi.org/10.1155/2021/8868370
  10. Farinati, F., Marino, D., De Giorgio, M., Baldan, A., Cantarini, M., Cursaro, C., Rapaccini, G., Del Poggio, P., Di Nolfo, M. A., Benvegnù, L., Zoli, M., Borzio, F., Bernardi, M., & Trevisani, F. (2006). Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. The American journal of gastroenterology, 101(3), 524–532. https://doi.org/10.1111/j.1572-0241.2006.00443.x
  11. Ji, J., Wang, H., Li, Y., Zheng, L., Yin, Y., Zou, Z., Zhou, F., Zhou, W., Shen, F., & Gao, C. (2016). Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PloS one, 11(4), e0153227. https://doi.org/10.1371/journal.pone.0153227

You May Also Like

18 September 2023

Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective

In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem. some of the challenges…

Read More
2 October 2023

Patient-centric and ecosystem insights into hepatocellular carcinoma across Asia-Pacific – LEAP

In this white paper, insights on the liver ecosystem are uncovered, with the intention of facilitating action among various stakeholders to reduce liver cancer incidence and mortality in APAC. Read…

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.